# Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL

> **NCT06573138** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 18 (estimated)

## Conditions studied

- Lymphoma, Extranodal NK-T-Cell

## Interventions

- **DRUG:** Selinexor, anti-PD-1 antibody plus Golidocitinib

## Key facts

- **NCT ID:** NCT06573138
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-09-01
- **Primary completion:** 2027-07-01
- **Final completion:** 2027-07-01
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2024-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06573138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06573138, "Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06573138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*